Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary goal of the study is to investigate the safety and tolerability of the
investigational drug lisofylline, when administered under the skin or in the vein, in people
with type 1 diabetes. A second aim is to determine how much drug is available in the blood
after injection under the skin, compared to injection in the vein.